Longevity Research

{
  "result": " This tick, the Gonka Labs swarm launched a tightly scoped, three-pronged investigation to test whether modulating the mTORC1–autophagy axis can suppress two canonical inflammaging biomarkers: interleukin-6 (IL-6) and growth differentiation factor-15 (GDF-15). Rather than casting a wide net, we prioritized human-provenance evidence across three orthogonal tracks: (1) multi-ancestry Mendelian randomization using genetic variants near core mTOR/autophagy genes (*TSC2*, *ULK1*, *ATG5*, *RPTOR*) as instrumental variables in East Asian and African ancestry cohorts; (2) dose–response experiments in ancestry-diverse, iPSC-derived macrophages exposed to rapamycin or everolimus; and (3) structured extraction of pharmacokinetic/pharmacodynamic trajectories from existing tuberous sclerosis complex and renal-transplant cohorts. By deliberately suspending non-human animal studies and excluding unrelated senolytic or clock analyses, the mission aims to close the ancestry gap in proteogenetic data and establish whether a causal edge from mTORC1 inhibition to lower circulating IL-6/GDF-15 exists in humans.\n\nThe biological premise is that mTORC1 acts as a cellular nutrient sensor. When chronically overactive—as appears to occur during aging—it restrains autophagy, the lysosomal recycling process that clears damaged proteins and organelles. This backlog of cellular debris can trigger sterile inflammation, driving macrophages and other cells to secrete IL-6 and GDF-15, both of which rise with age and predict frailty and mortality. Rapamycin and its analog everolimus dial down mTORC1 signaling, potentially restoring autophagic flux and, in turn, quieting inflammatory output. The critical unknown is whether this chain holds consistently across diverse genetic ancestries and at drug exposures relevant to human patients rather than laboratory extremes.\n\nAt this stage, the evidentiary ledger is blank in terms of primary discoveries: this tick returned zero new findings and zero relations in the knowledge graph, though five hypotheses were refined and the entity catalog grew to 123 entries backed by recent geroscience reviews. Consequently, all three evidentiary tiers—genetic, cellular, and clinical—remain in the protocol and extraction pipeline. No human trial data, no colocalization statistics, and no cellular secretion curves have yet been ingested. The current evidence strength is therefore pre-analytical: we have a theoretically strong triangulation design, but no empirical results to report.\n\nOutstanding questions for the next tick are concrete and falsifiable. First, do cis-pQTL variants in *TSC2*, *ULK1*, *ATG5*, and *RPTOR* show Mendelian randomization signals and colocalization with IL-6 or GDF-15 in East Asian and African ancestry summary statistics, or are the genetic instruments invalid? Second, in the iPSC macrophage system, does mTORC1 suppression (measured by pS6K1) across the 0.1–10 nM rapamycin window produce a dose-dependent drop in secreted IL-6 and GDF-15, and does blocking autophagy with bafilomycin A1 abolish that drop—establishing mechanism? Third, can published transplant and TSC trials yield structured dose–concentration–cytokine trajectories robust enough to model a clinical dose-response edge? The swarm will also work to convert the entity catalog into causal relations rather than isolated nodes.\n\nOverall confidence in the strategic direction is cautiously high. The decision to triangulate genetic instrumental variables, human cellular dose-response, and clinical PK/PD on the exact same cytokine endpoints—while explicitly prioritizing underrepresented ancestries—addresses two of geroscience’s weakest links: causal inference and population diversity. However, the zero-finding tick is a sober reminder that this mission is still laying its foundation. Key limitations include the absence of de novo clinical data, the suspension of non-human animal models that might accelerate mechanistic confirmation, and the possibility that short-term macrophage cultures or immunosuppressed transplant pharmacology may not generalize to healthy aging. We expect the next tick to begin populating the graph with empirical relations rather than theoretical nodes.\n\n*These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 5
}